logo
welcome
Reuters

Reuters

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Reuters
Summary
Nutrition label

79% Informative

Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates.

Monte Rosa will also be eligible for future payments of up to $2.1 billion as well as royalties on net sales outside the U.S. Shares of Monte Rosa surged 32% to $ 6.46 in premarket trade.

VR Score

89

Informative language

96

Neutral language

41

Article tone

formal

Language

English

Language complexity

68

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links